Obstructive Sleep Apnea



Fig. 24.1
Median systolic and diastolic BP changes after renal sympathetic denervation procedure at 3 and at 6 months of follow-up. Error bars represent interquartile range



Decreases in AHI at 3 months (non-significant) and at 6 months (with a tendency towards significance) after RDN were noted (median 16.3 events/h before RDN versus median 4.5 events/h after 6 months; p = 0.059). Also decreases in oxygen desaturation indices (ODI) at 6 months (median 13.0 events/h before RDN versus median 8.7 events/h; p = 0.11) and decreases in median Epworth Sleepiness Scale score at 6 months (9.00 points versus 7.00 points; p < 0.05) were also reported. In summary, in eight of ten patients an improvement in AHI was observed at 6 month (Fig. 24.2). There were two patients with mixed sleep apnea. In one of them, a reduction in sleep apnea indices was also observed with a change in AHI −30.5 events per hour at 6 months. In patients with improvement in AHI, a significant decrease in 24-h, daytime, and nighttime ambulatory Blood pressure monitoring (ABPM) levels was observed, the latter being most pronounced (median: −8/−4 mmHg, −12/−5 mmHg and −10/−8 mmHg for 24-h, daytime, and nighttime, respectively; p < 0.05 for all).

A312688_1_En_24_Fig2_HTML.jpg


Fig. 24.2
Changes of AHI at 3 and 6 months after denervation. Data of individual cases

Along with blood pressure reduction and sleep apnea course improvement significant decreases in plasma glucose concentration 2 h after glucose administration at 3 and at 6 months (median 7.0 mmol/dL versus median 6.4 mmol/dL at 6 months; p < 0.05) and in hemoglobin A1C level at 6 months (median 6.1 % versus median 5.6 %; p < 0.05) were demonstrated.

This study confirmed that RDN lowers blood pressure in patients with resistant hypertension [39, 40] and endorsed the work of Mahfoud et al. documenting that RDN in humans improves indices of insulin action and glucose metabolism [41]. However, this publication extended previous work by documenting that the blood pressure and metabolic benefits of renal denervation include patients with sleep apnea and improve the course of the disease. Because these data were observational, the study could not identify the exact mechanism responsible for any amelioration of sleep apnea. Nonetheless, it should be emphasized that RDN influences key mechanisms regulating sympathetic activation. The efferent sympathetic renal nerves can affect control of renal vascular resistance, increase renin release, and regulate sodium and water excretion [12]. The afferent renal nerves enhance the activity of the sympathetic nervous system. It has been also suggested that, in conditions of high-sodium dietary intake, activation of the afferent renal nerves contributes to the arterial baroreceptor-mediated suppression of efferent sympathetic renal nerves in the overall goal of preventing sodium retention and maintaining water and sodium homeostasis [12, 42]. Therefore, RDN in patients with resistant hypertension and OSA might attenuate the effects of sympathoactivation additionally and independently of CPAP treatment. Lastly, it need to be considered that the fall in blood pressure may itself contribute to the attenuation of sleep apnea.




Summary


Obstructive sleep apnea is potential independent risk factor for cardiovascular events, including ischemic heart disease, heart failure, stroke and death. Obstructive sleep apnea is also the most common disease associated with resistant hypertension. As both hypoxia and hypercapnia result in increased sympathetic activity, sympathetic nervous system plays a key role in the development of resistant hypertension in patients with obstructive sleep apnea. Sympathetic overactivation in OSA patients can worsen the prognosis of those patients with cardiovascular diseases, specifically by causing arrhythmias, myocyte injury and necrosis, peripheral vasoconstriction and the promotion of renal sodium retention, both directly and through stimulation of the renin-angiotensin-aldosterone axis. Preliminary results show that catheter-based renal sympathetic denervation may not only lower systolic blood pressure by ≈30 mmHg in resistant hypertensive patients with sleep disordered breathing but also improve sleep apnea severity. In eight of ten patients an improvement in apnea-hypopnea index was observed at 6 months after procedure. Along with blood pressure reduction and sleep apnea course improvement significant decreases in plasma glucose concentration 2 h after glucose administration in hemoglobin A1C level were observed.

Renal sympathetic denervation may conceivably be a potentially useful therapeutic option for this subset of patients; however large randomized controlled clinical trials are needed to confirm these initial proof-of-concept data.


References



1.

Punjabi NM. The epidemiology of adult obstructive sleep apnea. Proc Am Thorac Soc. 2008;5:136–43.PubMedCentralPubMedCrossRef


2.

Kasai T, Floras JS, Bradley TD. Sleep apnea and cardiovascular disease: a bidirectional relationship. Circulation. 2012;126:1495–510.PubMedCrossRef


3.

Pedrosa RP, Drager LF, Gonzaga CC, Sousa MG, de Paula LKG, Amaro ACS, Amodeo C, Bortolotto LA, Krieger EM, Bradley TD, Lorenzi-Filho G. Obstructive sleep apnea. The most common cause of hypertension associated with resistant hypertension. Hypertension. 2011;58:811–7.PubMedCrossRef


4.

Yumino D, Wang H, Floras JS, Newton GE, Mak S, Ruttanaumpawan P, Parker JD, Bradley TD. Prevalence and physiological predictors of sleep apnea in patients with heart failure and systolic dysfunction. J Card Fail. 2009;15:279–85.PubMedCrossRef


5.

Bassetti CL, Milanova M, Gugger M. Sleep-disordered breathing and acute ischemic stroke: diagnosis, risk factors, treatment, evolution, and long-term clinical outcome. Stroke. 2006;37:967–72.PubMedCrossRef


6.

Arzt M, Young T, Peppard PE, Finn L, Ryan CM, Bayley M, Bradley TD. Dissociation of obstructive sleep apnea from hypersomnolence and obesity in patients with stroke. Stroke. 2010;41:e129–34.PubMedCrossRef


7.

Logan AG, Perlikowski SM, Mente A, Tisler A, Tkacova R, Niroumand M, Leung RS, Bradley TD. High prevalence of unrecognized sleep apnea in drug-resistant hypertension. J Hypertens. 2001;19:2271–7.PubMedCrossRef


8.

Kohler M, Stradling JR. Mechanisms of vascular damage in obstructive sleep apnea. Nat Rev Cardiol. 2010;7:677–85.PubMed

Jun 20, 2017 | Posted by in NEPHROLOGY | Comments Off on Obstructive Sleep Apnea

Full access? Get Clinical Tree

Get Clinical Tree app for offline access